Korea’s Access Bio goes public, STIC PE expects 5x return
STIC Private Equity has made a partial exit from Korean biotech firm Access Bio after the company went public on the KOSDAQ exchange. The PE firm sold shares in two tranches – one just before the IPO and one during it – and has generated a money multiple of 2.3x. It now expects an overall return of around 5x on an investment of KRW12.5 billion ($11 million) made in 2011.
Access Bio - the first US-based biotech firm run by Korean scientists to list on KOSDAQ - priced its offering at KRW4,500 per share and the stock closed at KRW10,350 on its first day of trading on May...
More on Exits
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.